How Governments Control the Generic Drug Market in India, China, Brazil, and South Africa
A deep-dive strategic guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on the regulatory, patent, and […]
Pharmaceutical Patent and Regulatory Exclusivity: The Complete Strategic Playbook for Managing Overlaps, Defending Franchises, and Timing Market Entry
Who this is for: IP teams at innovator and generic companies, portfolio managers running LOE models, R&D leads evaluating lifecycle
Reverse Engineer Your Way to Generic Drug Dominance: The Complete Deformulation Playbook
The Market You’re Actually Competing In The generic drug industry saves the U.S. healthcare system more than $445 billion per
Reverse Engineer Your Way to Generic Drug Dominance: The Complete Deformulation Playbook Read Post »
Pharmaceutical Preliminary Injunctions: The Legal Weapon That Wins Before Trial
Who This Guide Is For This is not an overview. It is a field manual for IP counsel preparing a
Pharmaceutical Preliminary Injunctions: The Legal Weapon That Wins Before Trial Read Post »
Drug Patents vs. PTAB: The Dual-Track Strategy Guide That Wins Market Exclusivity
Introduction: Two Systems Built for Different Problems, Forced to Coexist In pharmaceutical patent law, the rules changed permanently on September
Drug Patents vs. PTAB: The Dual-Track Strategy Guide That Wins Market Exclusivity Read Post »
Brand Your Generic or Watch Competitors Own Your Market: The Data-Driven Decision Framework
The question sounds deceptively simple: should you put a brand name on your generic drug? In practice, it is one
Pharmaceutical Patent Pools: The Strategic Playbook Every Originator and Generic Needs Now
The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors
Small Molecules: The Pharmaceutical Industry’s Most Durable Strategic Asset
The pharmaceutical industry has spent much of the past decade performing a kind of collective memory erasure about small molecules.
Small Molecules: The Pharmaceutical Industry’s Most Durable Strategic Asset Read Post »
Paragraph IV Challenges: The Global Playbook for Generic Entry, Patent Wars, and the 180-Day Prize
A reference-grade guide for generic drug IP teams, litigation counsel, portfolio managers, business development executives, and institutional investors who need
